

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>UBS Oncology Impact Fund L.P.</u> (Last) (First) (Middle) <u>C/O MPM CAPITAL</u> <u>450 KENDALL STREET</u> (Street) <u>CAMBRIDGE MA 02142</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Harpoon Therapeutics, Inc. [HARP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/12/2019</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/12/2019		C		1,525,165	A	(I)	1,525,165	D ⁽²⁾⁽³⁾	
Common Stock	02/12/2019		C		1,578,755	A	(I)	3,103,920	D ⁽²⁾⁽³⁾	
Common Stock	02/12/2019		C		417,853	A	(I)	3,521,773	D ⁽²⁾⁽³⁾	
Common Stock	02/12/2019		x ⁽⁴⁾		127,096	A	\$0.0492	3,648,869	D ⁽²⁾⁽³⁾	
Common Stock	02/12/2019		s ⁽⁴⁾		447	D	\$14	3,648,422	D ⁽²⁾⁽³⁾	
Common Stock	02/12/2019		P		250,000	A	\$14	3,898,422	D ⁽²⁾⁽³⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(I)	02/12/2019		C		1,525,165	(I)	(I)	Common Stock	1,525,165	\$0.00	0	D		
Series B Preferred Stock	(I)	02/12/2019		C		1,578,755	(I)	(I)	Common Stock	1,578,755	\$0.00	0	D		
Series C Preferred Stock	(I)	02/12/2019		C		417,853	(I)	(I)	Common Stock	417,853	\$0.00	0	D		
Common Stock Warrant (Right to Buy)	\$0.0492	02/12/2019		x ⁽⁴⁾		76,258		11/01/2016 11/01/2026	Common Stock	76,258	\$0.00	0	D		
Common Stock Warrant (Right to Buy)	\$0.0492	02/12/2019		x ⁽⁴⁾		50,838		01/10/2017 01/10/2027	Common Stock	50,838	\$0.00	0	D		

1. Name and Address of Reporting Person*		
UBS Oncology Impact Fund L.P.		
(Last)	(First)	(Middle)
C/O MPM CAPITAL 450 KENDALL STREET		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
Oncology Impact Fund (Cayman) Management L.P.		
(Last)	(First)	(Middle)
C/O MPM CAPITAL 450 KENDALL STREET		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
MPM Oncology Impact Management LP		
(Last)	(First)	(Middle)
C/O MPM CAPITAL 450 KENDALL STREET		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
MPM Oncology Impact Management GP LLC		
(Last)	(First)	(Middle)
C/O MPM CAPITAL 450 KENDALL STREET		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		

Explanation of Responses:

- All series of convertible preferred stock will automatically convert into the number of shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
- The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadick is the Managing Member of Oncology GP LLC.
- The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
- On February 12, 2019, UBS Oncology exercised warrants to purchase an aggregate of 127,096 shares of the Issuer's common stock for \$0.0492 per share. UBS Oncology paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 447 of the warrant shares to pay the exercise price and issuing to UBS Oncology the remaining 126,649 shares.

Remarks:

/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P. 02/14/2019

/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P. 02/14/2019

/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP 02/14/2019

/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC 02/14/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.